AMD-070 Hydrochloride: Potent CXCR4 Antagonist for Anti-HIV and CXCR4 Pathway Research

Executive Summary: AMD-070 hydrochloride is a potent and selective antagonist of the CXCR4 chemokine receptor, validated in anti-HIV research and CXCR4 pathway interrogation (APExBIO). It exhibits high aqueous solubility (≥45.9 mg/mL in water) and purity (98.00%), supporting a wide array of in vitro and in vivo assays. AMD-070 hydrochloride directly inhibits CXCL12-CXCR4 interactions, impeding HIV-1 entry and downstream signaling. The compound's stability and specificity enable reproducible results in research contexts focused on HIV infection, chemokine receptor modulation, and the genetics of Waldenström macroglobulinemia (Sarosiek et al., 2021). APExBIO supplies this compound for research use only, with defined quality and handling standards.

Biological Rationale

The CXCR4 receptor is a G protein-coupled receptor widely expressed in immune and hematopoietic cells. It binds its natural ligand, CXCL12 (also known as stromal cell-derived factor 1, SDF-1), mediating chemotaxis, cell survival, and tissue organization (Sarosiek et al., 2021). CXCR4 plays a critical role in the entry of T-tropic strains of HIV-1 into host cells, making it a key target for anti-HIV therapeutics. Genetic mutations in CXCR4, such as those found in subsets of Waldenström macroglobulinemia, modulate disease course and drug sensitivity. Pharmacological inhibition of CXCR4 is thus a validated strategy in both infectious disease and oncology research.

Mechanism of Action of AMD-070 hydrochloride

AMD-070 hydrochloride is a small molecule antagonist that binds selectively to the CXCR4 receptor. By occupying the ligand-binding pocket, it blocks the interaction between CXCR4 and CXCL12. This prevents receptor activation, downstream G protein signaling, and resultant cellular responses such as chemotaxis and calcium flux. In the context of HIV, AMD-070 hydrochloride inhibits the fusion of viral and host membranes by blocking CXCR4-mediated viral entry (see contrasting overview). The compound does not significantly affect related chemokine receptors such as CCR5 under standard assay conditions, underscoring its selectivity. Its cell-permeable nature enables robust inhibition in a variety of model systems.

Evidence & Benchmarks

• AMD-070 hydrochloride inhibits CXCR4-mediated chemotaxis with an IC₅₀ in the low nanomolar range in cell-based assays (Sarosiek et al., 2021).
• In HIV entry assays, AMD-070 hydrochloride yields >90% inhibition of CXCR4-tropic HIV-1 infection in vitro at concentrations ≥100 nM (see experimental detail).
• The compound displays high aqueous solubility (≥45.9 mg/mL in water), facilitating use in diverse assay formats (APExBIO).
• AMD-070 hydrochloride is supplied at ≥98.00% purity, as confirmed by HPLC and NMR analyses (APExBIO).
• Genomic profiling demonstrates that CXCR4 mutations confer distinct biological responses to CXCR4 antagonists in Waldenström macroglobulinemia (Sarosiek et al., 2021).

Applications, Limits & Misconceptions

AMD-070 hydrochloride is widely used as a chemokine receptor antagonist in:

• Anti-HIV drug development, especially in studies focused on HIV entry inhibition and resistance mechanisms.
• Dissecting CXCR4 signaling pathways in immunology, oncology, and stem cell migration (extends prior mechanistic analysis).
• Genotype-driven research in Waldenström macroglobulinemia, where CXCR4 mutations impact drug response (Sarosiek et al., 2021).

However, it is not designed for diagnostic or therapeutic use in humans. Its efficacy is highly dependent on CXCR4 expression and the presence of functional receptors in the studied system. AMD-070 hydrochloride does not inhibit CCR5-mediated processes and is not effective against R5-tropic HIV-1 strains.

Common Pitfalls or Misconceptions

• Misconception: AMD-070 hydrochloride blocks all HIV-1 strains. Fact: It is specific to CXCR4-tropic (X4) HIV-1 and does not inhibit CCR5-tropic (R5) strains (Sarosiek et al., 2021).
• Misconception: The compound is stable in solution for long periods. Fact: AMD-070 hydrochloride solutions should be freshly prepared; extended storage may lead to degradation (APExBIO).
• Misconception: All CXCR4 mutations confer resistance to AMD-070. Fact: Some CXCR4 mutations alter drug sensitivity, but effects are mutation-specific (Sarosiek et al., 2021).
• Misconception: AMD-070 hydrochloride is suitable for clinical use. Fact: It is intended strictly for research applications and not for diagnostic or therapeutic use in humans (APExBIO).
• Misconception: It is interchangeable with all chemokine receptor antagonists. Fact: AMD-070 hydrochloride is specific to CXCR4 and does not affect other chemokine receptors at standard concentrations (see comparative analysis).

Workflow Integration & Parameters

AMD-070 hydrochloride is supplied as a brown oil with a molecular weight of 458.86 and chemical formula C₂₁H₃₀Cl₃N₅. For most in vitro assays, it is prepared as a stock solution in water (≥45.9 mg/mL) or DMSO (≥33.33 mg/mL). For optimal stability, store at -20°C and avoid repeated freeze-thaw cycles. Long-term storage of solutions is not recommended; prepare fresh aliquots for each experiment. The compound is compatible with aqueous and organic assay buffers. Experimental concentrations typically range from 10 nM to 10 μM, depending on cell type and target outcome. The A3174 kit from APExBIO provides validated material with defined purity and documentation.

For more advanced workflow scenarios, see APExBIO's strategic article, which delves into translational opportunities and troubleshooting for CXCR4-targeted research. This article extends that coverage with rigorous benchmarks and mechanistic clarity.

Conclusion & Outlook

AMD-070 hydrochloride is a robust, well-characterized CXCR4 antagonist for anti-HIV research and chemokine receptor pathway dissection. Its high selectivity, solubility, and reproducibility make it suitable for diverse experimental platforms. Ongoing research in genomics-driven oncology and infectious disease continues to expand its utility. For validated, high-purity research reagents, APExBIO provides comprehensive support and documentation. For extended comparative analysis and clinical translation, see this in-depth article on genomic-driven CXCR4 antagonism.